Drugs / APSLXR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04674735 | Jan 2023 → Jan 2025 | Meniere disease | Apsen Farmaceutica S.A. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APSLXR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674735 ↗ |
| Route | Oral | “Oral coated tablets once a day for 60 days.” NCT04674735 ↗ |